Evaluating combination therapies for asthma: pros, cons and comparative benefits
(2008) In Therapeutic Advances in Respiratory Disease 2(3). p.149-161- Abstract
- Combination therapies with inhaled corticosteroids (ICS) and either long-acting ß2 agonists (LABA) or leukotriene receptor antagonists (LTRA) are commonly used to help patients maintain control of their asthma. LABA and LTRA have different mechanisms of action and both provide complementary benefits when combined with ICS. This paper compares the two regimens based on recent clinical trial data, evaluates their efficacy on various clinical and quality of life outcomes, and discusses the importance of therapy choice in people with specific asthma phenotypes. The potential of new dosing strategies, including adjustable maintenance therapy and single-inhaler maintenance and reliever therapy is also reviewed. Given the variety of outcomes,... (More)
- Combination therapies with inhaled corticosteroids (ICS) and either long-acting ß2 agonists (LABA) or leukotriene receptor antagonists (LTRA) are commonly used to help patients maintain control of their asthma. LABA and LTRA have different mechanisms of action and both provide complementary benefits when combined with ICS. This paper compares the two regimens based on recent clinical trial data, evaluates their efficacy on various clinical and quality of life outcomes, and discusses the importance of therapy choice in people with specific asthma phenotypes. The potential of new dosing strategies, including adjustable maintenance therapy and single-inhaler maintenance and reliever therapy is also reviewed. Given the variety of outcomes, phenotypes, and treatment strategies that must be considered, the importance of individualized management is emphasized. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1275727
- author
- Bjermer, Leif LU
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Therapeutic Advances in Respiratory Disease
- volume
- 2
- issue
- 3
- pages
- 149 - 161
- publisher
- SAG
- external identifiers
-
- pmid:19124367
- scopus:68749098714
- pmid:19124367
- ISSN
- 1753-4666
- DOI
- 10.1177/1753465808092280
- language
- English
- LU publication?
- yes
- id
- db49d525-50ca-4c2c-8ef5-3197b9b42823 (old id 1275727)
- alternative location
- http://tar.sagepub.com/content/2/3/149.long
- http://www.ncbi.nlm.nih.gov/pubmed/19124367
- date added to LUP
- 2016-04-01 12:59:40
- date last changed
- 2022-01-27 08:40:33
@article{db49d525-50ca-4c2c-8ef5-3197b9b42823,
abstract = {{Combination therapies with inhaled corticosteroids (ICS) and either long-acting ß2 agonists (LABA) or leukotriene receptor antagonists (LTRA) are commonly used to help patients maintain control of their asthma. LABA and LTRA have different mechanisms of action and both provide complementary benefits when combined with ICS. This paper compares the two regimens based on recent clinical trial data, evaluates their efficacy on various clinical and quality of life outcomes, and discusses the importance of therapy choice in people with specific asthma phenotypes. The potential of new dosing strategies, including adjustable maintenance therapy and single-inhaler maintenance and reliever therapy is also reviewed. Given the variety of outcomes, phenotypes, and treatment strategies that must be considered, the importance of individualized management is emphasized.}},
author = {{Bjermer, Leif}},
issn = {{1753-4666}},
language = {{eng}},
number = {{3}},
pages = {{149--161}},
publisher = {{SAG}},
series = {{Therapeutic Advances in Respiratory Disease}},
title = {{Evaluating combination therapies for asthma: pros, cons and comparative benefits}},
url = {{https://lup.lub.lu.se/search/files/3095347/1275730.pdf}},
doi = {{10.1177/1753465808092280}},
volume = {{2}},
year = {{2008}},
}